Zynerba Pharmaceuticals (NASDAQ:ZYNE) Lowered to Hold at ValuEngine

ValuEngine downgraded shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) from a buy rating to a hold rating in a research report released on Tuesday, May 28th, ValuEngine reports.

Other equities research analysts have also recently issued reports about the company. LADENBURG THALM/SH SH reissued a buy rating and issued a $26.00 target price on shares of Zynerba Pharmaceuticals in a research note on Monday, May 6th. Roth Capital assumed coverage on Zynerba Pharmaceuticals in a report on Tuesday, April 30th. They set a buy rating and a $36.00 price target on the stock. Canaccord Genuity started coverage on Zynerba Pharmaceuticals in a report on Monday, April 22nd. They issued a buy rating and a $8.09 target price on the stock. Zacks Investment Research raised Zynerba Pharmaceuticals from a hold rating to a buy rating and set a $7.00 price objective on the stock

... read more at: https://rocklandregister.com/2019/06/05/zynerba-pharmaceuticals-zyne-lowered-to-hold-at-valuengine.html